Advanced science (Weinheim, Baden-Wurttemberg, Germany)

New Polymer and Lipid Options for Improving Lipid Nanoparticle Formulations Beyond PEG

Updated

Abstract

Lipid nanoparticles (LNPs) are the leading delivery platform for nucleic acid therapeutics due to their high encapsulation efficiency and scalable manufacturing.

  • Poly(ethylene glycol)-lipids (PEG-lipids) enhance steric stabilization and size control but also introduce limitations such as complement activation and anti-PEG antibodies.
  • Accelerated blood clearance associated with PEGylation constrains repeated and long-term dosing strategies for LNPs.
  • Recent advances in LNP designs include non-PEG polymers, zwitterionic lipids, polypeptides, and modified PEG analogues.
  • The properties of LNPs, including formation, biodistribution, and cellular uptake, are influenced by factors such as polymer chemistry and grafting architecture.
  • Challenges remain in the clinical application of PEG-free and PEG-modified LNPs, highlighting the need for further research into their in vivo behavior.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free